Rating Change
Piper Sandler analysts reiterated a Overweight rating on TransMedics Group, Inc. (NASDAQ:TMDX) on August 05, 2026.
reiterateNASDAQ:TMDX
Piper Sandler Reiterates Overweight Rating on TransMedics Group, Inc. (TMDX)
Rating Change Piper Sandler analysts reiterated a Overweight rating on TransMedics Group, Inc. (NASDAQ:TMDX) on August 05, 2026. Market Context TransMedics Group, Inc.
Market Context
TransMedics Group, Inc. operates in the Healthcare sector. The stock currently trades at $76.49 with a market capitalization of $4.4B.
Analyst coverage from Piper Sandler provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for TransMedics Group, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for TransMedics Group, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 05, 2026 | Piper Sandler | Overweight | N/A |
| Aug 03, 2026 | Needham | Buy | N/A |
| Jul 28, 2026 | UBS | Neutral | N/A |
| Jul 06, 2026 | Evercore ISI Group | Outperform | N/A |
| Jul 01, 2026 | TD Cowen | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View TMDX Stock Page
Frequently Asked Questions
What does a Overweight rating mean for TMDX?
A Overweight rating from Piper Sandler reflects the analyst's outlook on TransMedics Group, Inc. (NASDAQ:TMDX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TMDX forecast page.